About Scynexis
Scynexis is a publicly listed company based in Jersey City (United States) founded in 1999. Scynexis has raised $62.65 million across 9 funding rounds from investors including Société Générale, SLR Investment Corp and Burrill and Company. The company has 28 employees. Its chief executive, as recorded, is Marco Taglietti. Scynexis offers products and services including SCY-247 and Ibrexafungerp. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Fungal. Its legal entity is SCYNEXIS, Inc. Its competitors include Amplyx Pharmaceuticals, Elion Therapeutics and Viamet Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Developing glucan synthase inhibitors for the treatment of fungal infections. The companys lead candidate is SCY-078, which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections. SCY-078 acts as a glucan synthase inhibitor against a broad range of Candida and Aspergillus species.
- Headquarters Jersey City, United States
- Employees 28
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website scynexis.com
- Social LinkedIn X
- Legal Name Scynexis, Inc.
- Annual Revenue$20.6 M (USD)449.95as on Dec 31, 2025
- Net Profit-$8.61 M (USD)59.56as on Dec 31, 2025
- EBITDA-$16.07 M (USD)56.69as on Dec 31, 2025
- Total Equity Funding$62.65M (USD)
in 9 rounds
- Latest Funding Round$10M (USD), Post-IPO
Apr 2020
- InvestorsSociété Générale
& 10 more
- Employee Count28
Products & Services of Scynexis
Scynexis offers a comprehensive portfolio of products and services, including SCY-247 and Ibrexafungerp.
Second-generation agent for treating invasive fungal infections
Novel therapy against serious fungal pathogens
Funding Insights of Scynexis
Scynexis has successfully raised a total of $62.65M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62.65M
- Total Rounds 9
- Last Round Post-IPO — $10M
- First Round $29M
(Jun 2002)
- Investors Count 11
All 9 funding rounds of Scynexis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $10M | Post-IPO | – | – | |
| Sep 2016 | $15M | Debt – Conventional | – | – | |
| May 2012 | $11.45M | Series D | – | – | – |
| Dec 2011 | $5M | Debt – Conventional | – | – | |
| Dec 2011 | $5.5M | Series D | – | Alta Partners, KBL | – |
| Nov 2010 | $977,917 | Grant | – | – | |
| Mar 2008 | $13.5M | Series C | – | – | |
| Mar 2006 | $3.2M | Series C | – | – | – |
| Jun 2002 | $29M | Series C | – | – |
11 investors in total: 11 institutional.
Investors in Scynexis
Scynexis has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Société Générale, SLR Investment Corp and Burrill and Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Debt and equity investments are offered by the firm. | 2006 | solarcapltd.com | New York, United States | |
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Limited information is provided about KBL Healthcare Ventures. | kblhealthcare.com | |||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
| kblvc.com | ||||
Manages diversified investment portfolios across multiple asset classes. | 2015 | puissancecapital.com | New York, United States | |
Full-service corporate advisory is provided to global clients. | 1864 | societegenerale.com | Paris, France | |
Ventech Solutions is engaged in delivering technology transformation services. | ventechsolutions.com | Round Rock, United States | ||
Tax administration and collection services by the US government. | irs.gov | |||
Animal health pharmaceuticals and vaccines are developed and produced. | 1997 | merial.com | Duluth, United States |
Investor details for Scynexis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Scynexis
21 people are tracked at Scynexis (12 in leadership, 6 in board & advisors, 3 in team); the tracked headcount is 28.
| Name | Role | Group |
|---|---|---|
Marco Taglietti | CEO | Leadership |
Michelle Quintana | Executive Director, IT & Human Resources | Leadership |
Rossana Ferrara-Pontoriero | VP, Business Development & Alliance Management | Leadership |
Jane Soong | Executive Director, Finance | Leadership |
Christopher Anastasi | Associate Director Clinical Operations | Leadership |
David Angulo | President & CEO | Leadership |
Scott Sukenick | Chief Legal Officer | Leadership |
Ivor Macleod | Chief Financial Officer | Leadership |
Daniella Gigante | VP, Human Resources & Information Technology | Leadership |
Yang Li | Associate Director, CMC QA | Leadership |
Lori Tierney | Executive Director, Clinical Operations | Leadership |
Dipa Ramolia | Senior Director | Leadership |
Guy Macdonald | Chairman | Board & advisors |
Ann F. Hanham | Director | Board & advisors |
Armando Anido | Director | Board & advisors |
David Hastings | Director | Board & advisors |
Philippe Tinmouth | Director | Board & advisors |
Steven C. Gilman | Director | Board & advisors |
Deirdre Archibald | Executive and Operations Manager | Team |
Paul Antenucci-Fucetola | Senior Project Manager | Team |
1 more people are available in the full profile.
Complete people profiles for Scynexis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Scynexis
Scynexis is a publicly listed company on the NASDAQ with ticker symbol SCYX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Sep 2021
- Listed onLSE: 0L49
- Listed entitySCYNEXIS, Inc.
- Exchange sectorHealth technology
- ISINUS8112923094
- Share price$3.99 (-0.99% on the day) · 2026-10-13
- Market capitalisation$39.7M
- EPS (diluted, trailing year)$-1.84
- Volume (last session)66,761
Financials of Scynexis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $20.6M | -$8.6M | -$16.1M |
| 2024 | $3.8M | -$21.3M | -$37.1M |
| 2023 | $140.1M | $67.0M | $73.5M |
| 2022 | $5.1M | -$62.8M | -$84.9M |
| 2021 | $13.2M | -$32.9M | -$60.3M |
Detailed financial statements for Scynexis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Scynexis
4 dated milestones of Scynexis across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Scynexis is founded.
- Funding First funding round of $29.0M.
- Funding Latest funding round, Post-IPO, of $10.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Scynexis
Scynexis has 3 listed competitors in our database, 3 of them funded. They include Amplyx Pharmaceuticals, Elion Therapeutics and Viamet Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amplyx.com | 2006 | San Diego, United States | $144.31M | 15 | Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma. | |
| eliontx.com | 2024 | New York, United States | $81M | Therapeutics for invasive fungal infections are developed by Elion Therapeutics. | ||
| viamet.com | 2005 | Durham, United States | $160.8M | 22 | Therapies for chronic fungal infections are developed using metalloenzyme inhibitors. |
Detailed competitors of Scynexis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Scynexis
The website of Scynexis (scynexis.com) receives about 6.5K visits a month and ranks #4,483,848 among all websites worldwide, #5,418 in Biotechnology and Pharmaceuticals.
- Monthly visits6.5K
▲ 71.4% vs previous month
- Unique visitors1.7K
per month
- Global rank#4,483,848
among all websites
- Category rank#5,418
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.9
- Average visit29 sec
- DevicesDesktop 48% · Mobile 52%
Websites whose visitors overlap most with Scynexis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| apcerls.com | 100% | #3,323,878 | View details | ||
| brainstorm-cell.com | 99% | 4.5K | #4,620,847 | View details | |
mt-pharma-america.com | mt-pharma-america.com | 97% | #11,554,805 | – | |
| fortressbiotech.com | 94% | 11.6K | #2,326,761 | View details | |
| jubilantbiosys.com | 75% | 12.2K | #2,731,637 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Scynexis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Scynexis (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Scynexis
Complete news archive for Scynexis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scynexis
Scynexis was founded in 1999 and raised its 1st funding round 3 years after it was founded.
Scynexis is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
Marco Taglietti is the CEO of Scynexis, as recorded in our data.
Scynexis is a funded company, having raised a total of $62.65M across 9 funding rounds to date. The company's 1st funding round was a Series C of $29M, raised on Jun 2002.
Scynexis has 28 employees.
Annual revenue of Scynexis is $20.6M as on Dec 31, 2025.
Developing glucan synthase inhibitors for the treatment of fungal infections. The companys lead candidate is SCY-078, which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections. SCY-078 acts as a glucan synthase inhibitor against a broad range of Candida and Aspergillus species.
Scynexis's top competitors include Amplyx Pharmaceuticals, Viamet Pharmaceuticals and Elion Therapeutics.
Scynexis offers SCY-247 and Ibrexafungerp.
Yes, Scynexis is publicly traded on NASDAQ under the ticker symbol SCYX.
Scynexis has 11 investors. Key investors include Société Générale, SLR Investment Corp, Burrill and Company, Merial, and Puissance Capital.
Scynexis operates through Scynexis, Inc..